Citations

Clear

815 citation(s) found for "Tang, Yu".

Multiparametric MRI detects longitudinal evolution of folic acid-induced nephropathy in mice
Jiang, Kai , Ponzo, Tristan A., Tang, Hui , Mishra, Prasanna K. , Lerman, Lilach O. , Macura, Slobodan I, Macura, Slobodan

Mayo Clinic

American Journal of Physiology-Renal Physiology | August 8, 2018 | Volume: 315 | Issue: 5 | Pages: F1252-F1260

10.1152/ajprenal.00128.2018 | PMID 30089037 Get It

The rodent model of folic acid (FA)-induced acute kidney injury (AKI) provides a useful model for studying human AKI, but little is known about longitudinal changes in renal hemodynamics and evolution of renal fibrosis in vivo. In this work, we aimed to longitudinally assess renal structural and functional changes using multiparametric magnetic resonance imaging (MRI). Ten adult mice were injected with FA, after which a multiparametric MRI was used to measure kidney volume, hypoxia index R2*, magnetization transfer ratio (MTR), perfusion, T1, and glomerular filtration rate (GFR) at 2 wk posttreatment. Then five mice were euthanized for histology, and the other five underwent MRI again at 4 wk, followed by histology. Control mice ( n = 5) were injected with vehicle and studied with MRI at 2 wk. Trichrome and hematoxylin-eosin staining were performed to assess FA-induced tissue injuries. Whereas kidney size and oxygenation showed progressive deterioration, a transient impairment in renal perfusion and normalized GFR slightly improved by 4 wk. Kidney fluid content, as reflected by T1, was prominent at 2 wk and tended to regress at 4 wk, consistent with observed tubular dilation. Trichrome staining revealed patchy necrosis and mild interstitial fibrosis at 2 wk, which exacerbated at 4 wk. MTR detected increased fibrosis at 4 wk. In conclusion, multiparametric MRI captured the longitudinal progression in kidney damage evolving within the first month after treatment with folic acid and may provide a useful tool for assessment of therapeutic strategies.
Posttraumatic Stress Disorder in Patients with Heavy Alcohol Consumption and Alcoholic Hepatitis
Samala, Niharika , Lourens, Spencer, Shah, Vijay H. , Kamath, Patrick S. , Crabb, David W. , Tang, Qing , Radaeva, Svetlana , Liangpunsakul, Suthat , Chalasani, Naga , Crabb, David W , Liangpunsakul, Suthat , Sanyal, Arun J.

Mayo Clinic

Alcoholism: Clinical and Experimental Research | August 7, 2018 | Volume: 42 | Issue: 10 | Pages: 1933-1938

10.1111/acer.13862 | PMID 30080255 Get It

BackgroundLifetime prevalence of posttraumatic stress disorder (PTSD) in the general population is reported to be 6.8%. Individuals with alcohol dependence and substance abuse have high prevalence of PTSD. However, the prevalence of PTSD in heavy drinkers with alcoholic hepatitis (AH) is not known.The study's aim was to determine the prevalence of PTSD in heavy drinkers with and without AH.MethodsWe screened for PTSD using the Primary Care‐PTSD questionnaire among heavy drinkers with (n = 115) and without (n = 64) AH participating in a multicenter observational study in which participants were followed up to 12 months following their enrollment.ResultsThe prevalence of PTSD in heavy drinkers with AH was 34% and was not different from heavy drinking controls without liver disease (34%). In the entire group screened for PTSD, the presence of PTSD was associated with higher alcohol consumption as reported by average drinks per last 30 days and average grams of alcohol consumed per day (p = 0.047 for both tests), but not associated with relapse of heavy drinking or mortality. Similarly, patients with AH and PTSD did not have higher relapse rate or higher mortality compared to patients with AH but no PTSD.ConclusionsCompared to previously reported prevalence in general population, heavy drinking individuals with or without AH have significantly higher prevalence of PTSD. However, PTSD was not associated with higher relapse rate or higher mortality in this population.
Objective but Not Subjective Short Sleep Duration Is Associated With Hypertension in Obstructive Sleep Apnea
Ren, Rong , Covassin, Naima , Yang, Linghui , Zhang, Ye , Zhou, Junying , Tan, Lu, Li, Taomei , Li, Xiao , Wang, Yanyan , Zhang, Jihui , Tang, Xiangdong , Tang, Xiangdong , Li, Yun , Tan, Lu, Wing, Yun Kwok , Li, Weimin , Somers, Virend K.

Mayo Clinic

Hypertension | July 9, 2018 | Volume: 72 | Issue: 3 | Pages: 610-617

10.1161/hypertensionaha.118.11027 | PMID 29987105 Get It

Extremes of sleep duration and obstructive sleep apnea (OSA) are both associated with hypertension. We aimed to explore whether sleep duration modifies the relationship between OSA and prevalent hypertension, using both objective and subjective measures of total sleep duration. A total of 7107 OSA patients and 1118 primary snorers were included in the study. Hypertension was defined based either on direct blood pressure measures or on diagnosis by a physician. Objective sleep duration was derived by polysomnography and subjective sleep duration was self-reported. Logistic regression models were used to estimate the associations between objective/subjective sleep duration and hypertension prevalence in OSA and primary snorers. Compared with primary snorers, OSA combined with objective sleep duration of 5 to 6 hours increased the odds of hypertension by 45% (odds ratio, 1.45; 95% confidence interval, 1.14–1.84), whereas OSA combined with objective sleep duration <5 hours further increased the odds of hypertension by 80% (odds ratio, 1.80; 95% confidence interval, 1.33–2.42). These results were independent of major confounding factors frequently associated with OSA or hypertension. In stratified analysis by sleep duration, risk of hypertension in those with extremely short sleep (<5 hours) was not significantly different between OSA and primary snorers, whereas odds were significant for OSA in the other 4 sleep duration strata (5–6, 6–7, 7–8, and >8 hours). No significance was evident using subjective sleep duration. We conclude that objective short sleep duration is associated with hypertension in OSA patients. Extremely short sleep duration in itself may actually be even more detrimental than OSA in terms of hypertension risk.
Simultaneous reconstruction of the thumb defect and coverage of the failed first dorsal metacarpal artery flap donor site by using the anterolateral thigh flap and its vascular pedicle tissue
Liu, En‐Wei , Huang, Tony Chieh‐Ting , Cheng, Hsu‐Tang , Cheng, Hsu-Tang

Mayo Clinic

Microsurgery | June 27, 2018 | Volume: 38 | Issue: 7 | Pages: 821-822

10.1002/micr.30347 | PMID 29947062 Get It

Minimally invasive preservation versus splenectomy during distal pancreatectomy: a systematic review and meta‐analysis
Nakata, Kohei , Shikata, Satoru , Ohtsuka, Takao , Miyasaka, Yoshihiro , Mori, Yasuhisa , Velasquez, Vittoria Vanessa, Gotoh, Yoshitaka , Ban, Daisuke , Tanabe, Minoru , Sahara, Yatsuka, Takaori, Kyoichi , Misawa, Takeyuki , Yamaue, Hiroki , Morikawa, Takanori , Kuroki, Tamotsu, Mou, Yiping , Lee, Woo Jung , Shrikhande, Shailesh V. , Tang, Chung Ngai, Conrad, Claudius , Chinnusamy, Palanivelu, Asbun, Horacio J. , Kooby, David A. , Wakabayashi, Go , Takada, Tadahiro , Yamamoto, Masakazu , Nakata, Kohei , Ukai, Tomohiko , Nakamura, Yoshiharu , Nagakawa, Yuichi , Honda, Goro , Kawai, Manabu , Han, Ho-Seong , Nakamura, Masafumi

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | June 26, 2018 | Volume: 25 | Issue: 11 | Pages: 476-488

10.1002/jhbp.569 | PMID 29943909 Get It

AbstractBackgroundMinimally invasive distal pancreatectomy (MIDP) has gained in popularity recently. However, there is no consensus on whether to preserve the spleen or not. In this study, we compared MIDP outcomes between spleen‐preserving distal pancreatectomy (SPDP) and distal pancreatectomy with splenectomy (DPS); as well as outcomes between splenic vessel preservation (SVP) and Warshaw's technique (WT).MethodsA systematic search of PubMed (MEDLINE) and Cochrane Library was conducted and the reference lists of review articles were hand‐searched.ResultsFifteen relevant studies with 769 patients were selected for meta‐analyses of DPS and SPDP, while another 15 studies with 841 patients were used for the analysis between SVP and WT. Compared with the DPS group, SPDP patients had significantly lower incidences of infectious complications (P = 0.006) and pancreatic fistula (P = 0.002), shorter operative time (P < 0.001), and less blood loss (P = 0.01). Compared with WT, SVP patients had significantly lower incidences of splenic infarction (P < 0.001) and secondary splenectomy (P = 0.003). Subanalysis for laparoscopic surgery alone had similar results.ConclusionsBased on this study, SPDP has significantly superior outcomes compared to DPS. When a spleen is preserved, SVP has better outcomes over WT for reducing splenic complications.
Spectrum of Pitfalls, Pseudolesions, and Misdiagnoses in Noncirrhotic Liver
Elsayes, Khaled M. , Menias, Christine O. , Morshid, Ali , Shaaban, Akram M. , Fowler, Kathryn J. , Tang, An , Chernyak, Victoria , Szklaruk, Janio , Bashir, Mustafa R. , Szklaruk, Janio , Fowler, Kathryn J

Mayo Clinic

American Journal of Roentgenology | June 22, 2018 | Volume: 211 | Issue: 1 | Pages: 97-108

10.2214/ajr.18.19820 | PMID 29932762 Get It

Utility of the Psychosocial Assessment of Candidates for Transplantation in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implantation
Halkar, Meghana , Nowacki, Amy S. , Kendall, Kay, Efeovbokhan, Nephertiti , Moazami, Nader , Lee, Sangjin , Tang, W.H. Wilson , Tang, W H Wilson , Gorodeski, Eiran Z. , Starling, Randall C. , Young, James B.

Mayo Clinic

Progress in Transplantation | June 8, 2018 | Volume: 28 | Issue: 3 | Pages: 220-225

10.1177/1526924818781559 | PMID 29879864 Get It

Purpose: Psychosocial assessment of patients comprises an important element in the selection process of appropriate candidates for left ventricular assist device (LVAD) implantation. We sought to determine the association of the well-validated psychosocial assessment of candidates for transplantation (PACT) scale to clinical outcomes post-LVAD implantation. Materials and Methods: The PACT scale was used retrospectively to reconstruct psychosocial profiles of all patients who underwent a continuous-flow LVAD implantation for all indications at our institution between March 2008 and August 2012 (N = 230). Psychosocial elements including social support, psychological health, lifestyle factors, comprehension of the operation, and follow-up were evaluated. The primary outcome was overall survival, and the secondary outcomes were hospital readmission, pump thrombosis, hemolysis, gastrointestinal (GI) bleeding, and LVAD driveline infections. Results: The mean age of patients was 55.3 years, with 83% being male; 58% (N = 135) were bridge to transplant and 42% (N = 95) were destination therapy. Up to 1-year post-LVAD implant, there were no statistical differences among the 5 PACT candidate groups in terms of survival ( P = .79), hospital readmissions ( P = .55), suspected or confirmed pump thrombosis ( P = .31), hemolysis ( P = .43), GI bleeding ( P = .71), or driveline infections ( P = .06). Conclusions: In this single-center retrospective review, post hoc reconstruction of psychosocial profiles using the PACT scale and independent assessment of postimplant outcomes, including survival and adverse events, did not show any association. However, given the small number of patients in the low score PACT groups as well as limited duration of follow-up, further studies are required to elucidate the association.
New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia
Khachaturian, Ara S. , Hayden, Kathleen M. , Mielke, Michelle M. , Lutz, Michael W. , Gold, Michael , Kukull, Walter A. , Mohs, Richard C. , Gauthier, Serge , Khachaturian, Zaven S., Mielke, Michelle M , Tang, Yi , Molinuevo, José Luís , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | May 26, 2018 | Volume: 14 | Issue: 6 | Pages: 703-706

10.1016/j.jalz.2018.05.002 | PMID 29842864 Get It

A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology
Sciver, Robert E. Van , Lee, Michael , Lafever, Alex, Svyatova, Elizaveta , Kanda, Kevin, Collier, Amber L. , Reesema, LL Siewertsz van, Tang-Tan, Angela M., Zheleva, Vasilena, Bwayi, Monicah, Bian, Minglei, Schmidt, Rebecca L., Matrisian, Lynn M. , Petersen, Gloria M. , Van Sciver, Robert E , Matrisian, Lynn M , Lee, Caroline Guat Lay , Tang, Amy

Mayo Clinic

Cancers | May 15, 2018 | Volume: 10 | Issue: 5 | Pages: 142

10.3390/cancers10050142 | PMID 29757973 Get It

Oncogenic K-RAS mutations are found in virtually all pancreatic cancers, making K-RAS one of the most targeted oncoproteins for drug development in cancer therapies. Despite intense research efforts over the past three decades, oncogenic K-RAS has remained largely “undruggable”. Rather than targeting an upstream component of the RAS signaling pathway (i.e., EGFR/HER2) and/or the midstream effector kinases (i.e., RAF/MEK/ERK/PI3K/mTOR), we propose an alternative strategy to control oncogenic K-RAS signal by targeting its most downstream signaling module, Seven-In-Absentia Homolog (SIAH). SIAH E3 ligase controls the signal output of oncogenic K-RAS hyperactivation that drives unchecked cell proliferation, uncontrolled tumor growth, and rapid cancer cell dissemination in human pancreatic cancer. Therefore, SIAH is an ideal therapeutic target as it is an extraordinarily conserved downstream signaling gatekeeper indispensable for proper RAS signaling. Guided by molecular insights and core principles obtained from developmental and evolutionary biology, we propose an anti-SIAH-centered anti-K-RAS strategy as a logical and alternative anticancer strategy to dampen uncontrolled K-RAS hyperactivation and halt tumor growth and metastasis in pancreatic cancer. The clinical utility of developing SIAH as both a tumor-specific and therapy-responsive biomarker, as well as a viable anti-K-RAS drug target, is logically simple and conceptually innovative. SIAH clearly constitutes a major tumor vulnerability and K-RAS signaling bottleneck in pancreatic ductal adenocarcinoma (PDAC). Given the high degree of evolutionary conservation in the K-RAS/SIAH signaling pathway, an anti-SIAH-based anti-PDAC therapy will synergize with covalent K-RAS inhibitors and direct K-RAS targeted initiatives to control and eradicate pancreatic cancer in the future.